Study Findings from M.F. Rezk et al Provide New Insights into Biosimilars (To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of...

Biotech Week |

Study Findings from M.F. Rezk et al Provide New Insights into Biosimilars (To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars)

By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Drugs and Therapies - Biosimilars are discussed in a new report. According to news reporting originating in Zug, Switzerland, by NewsRx journalists, research stated, "In addition to the general clinical benefit offered, biosimilars may not only generate savings for healthcare budgets but also improve patient access to biologic products. Since the first biosimilar was approved in Europe in 2006, a further 36 different biosimilar drugs have been approved for several indications."

Financial support for this research came from Biogen International GmBH (see also Drugs and Therapies - Biosimilars).

The news reporters obtained a quote from the research, "Despite the wealth of experience gained and the reported data supporting the use of biosimilars, both in na < ve and biologic-experienced patients, some healthcare professionals continue to express doubt regarding the rigorous approval process for biosimilars and uncertainty with how to incorporate them into daily clinical practice. These opinions can be transferred to patients through poor or lack of communication, meaning that patients may lack confidence in treatment quality and, as a result, be susceptible to the nocebo effect. At the 2017 American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting, during a debate the question was asked as to whether the nocebo effect was in fact being used to describe 'any result you don't agree with'. Here, we detail that the nocebo effect has been demonstrated in a number of clinical trials, and that this effect may negatively affect acceptance in patients switching from an originator product to a biosimilar. Awareness of the potential for the nocebo effect and adoption of enhanced communication techniques may be useful in mitigating the nocebo effect."

According to the news reporters, the research concluded: "Effective healthcare professional-patient dialogue is key in transferring confidence to the patient, and has been shown to reduce nocebo effects in patients when switching from an originator to a biosimilar. Biogen International GmbH."

For more information on this research see: To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars. Advances in Therapy, 2018;35(6):749-753. Advances in Therapy can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer -; Advances in Therapy -

Our news correspondents report that additional information may be obtained by contacting M.F. Rezk, Biogen Int GmbH, Zug, Switzerland.

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Zug, Switzerland, Europe, Healthcare Biotechnology Companies, Biopharmaceutical Companies, Health and Medicine, Drugs and Therapies, Biosimilars, Business.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Dominic Briggs General Partner Blockwall Management

Matt Bird sits down with Dominic Briggs, General Partner Blockwall Management at the World Economic Forum at Davos 2019